What are the Merck tablets that the “World Health” recommended to use against “Corona” infection?
The World Health Organization has recommended the approval of the American company Merck's anti-coronavirus (Covid-19) tablets for the treatment of patients with still mild symptoms, but who are at risk of hospitalization.
And an international group of experts affiliated with the World Health Organization announced to the British Medical Journal, that this drug, “molnopiravir” is recommended “for people with mild symptoms of Covid-19 and at risk of hospitalization more than others.”
According to “AFP”, the World Health Organization clarified in a statement that the recommendation is based on new data issued by six trials based on observing a random sample of 4796 patients, which is the largest data set on this drug so far.
Patients at risk of hospitalization are the unvaccinated, the elderly, and immunocompromised or chronically ill persons.
On the other hand, the group said that "young patients and those who are in good health, including children and pregnant and lactating women" should not take the treatment.
Molnopiravir is an antiviral drug, and it must be taken immediately after symptoms appear, and for five days to prevent the virus from multiplying.
The results of the trials aim to demonstrate that “molnopiravir” reduces the risk of hospitalization (a reduction of 43 hospitalizations from 1,000 patients at risk) and the time required for symptoms to subside (on average, 3.4 days less).
Follow our latest local and sports news and the latest political and economic developments via Google news